Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer

被引：0
|
作者：
Keun-Wook Lee
Yu Jung Kim
Kyung-Hun Lee
Sae-Won Han
Tae-Yong Kim
Do-Youn Oh
Seock-Ah Im
Tae-You Kim
Yung-Jue Bang
In Sil Choi
Jee Hyun Kim
机构：
[1] Seoul National University College of Medicine,Department of Internal Medicine, Seoul National University Bundang Hospital
[2] Seoul National University College of Medicine,Department of Internal Medicine, Seoul National University Hospital
[3] Seoul National University College of Medicine,Department of Internal Medicine, SMG
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Metastatic colorectal cancer; Chemotherapy; Refractory; Gemcitabine; UFT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：447 / 455
页数：8
相关论文
共 50 条
  • [1] Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
    Lee, Keun-Wook
    Kim, Yu Jung
    Lee, Kyung-Hun
    Han, Sae-Won
    Kim, Tae-Yong
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    Choi, In Sil
    Kim, Jee Hyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 447 - 455
  • [2] Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    Sheikh, H. Y.
    Valle, J. W.
    Waddell, T.
    Palmer, K.
    Wilson, G.
    Sjursen, A.
    Craven, O.
    Swindell, R.
    Saunders, M. P.
    BRITISH JOURNAL OF CANCER, 2008, 99 (04) : 577 - 583
  • [3] Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    H Y Sheikh
    J W Valle
    T Waddell
    K Palmer
    G Wilson
    A Sjursen
    O Craven
    R Swindell
    M P Saunders
    British Journal of Cancer, 2008, 99 : 577 - 583
  • [4] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [5] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [6] Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer
    Mibu, R.
    Tanaka, S.
    Futami, K.
    Shimada, K.
    Hotokezaka, M.
    Nakahara, S.
    Ichimiya, H.
    Kido, H.
    Hirano, Y.
    Kashiwagi, T.
    Eguchi, T.
    Mitsuki, K.
    Mizumoto, K.
    Tanaka, M.
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2673 - 2677
  • [7] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [8] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Craven, O.
    Wilson, G.
    Swindell, R.
    Saunders, M. P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 38 - 43
  • [9] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    H Y Sheikh
    J W Valle
    K Palmer
    A Sjursen
    O Craven
    G Wilson
    R Swindell
    M P Saunders
    British Journal of Cancer, 2007, 96 : 38 - 43
  • [10] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
12345